{
    "confidence": 0.5,
    "enhanced_text": {
        "Patient Name": "Mr. SURESH KACHARU SHIROSE",
        "hospital_lab_location": "NA",
        "hospital_lab_name": "Aba Ves Sciences",
        "parameters": [
            {
                "clinicalHistory": "Clinical Case of carcinoma thyroid in bone",
                "comments": "PDI.1 interpretation:\nClone: Roche SP263\nSite umor Cell score (TC) omb ined Proportion Score Result\nCPS)\nPD-L.1 Expression Level No PIDL.1 expression\n[Non-Small Cell Lung< 1% Negative)\nk 1,2 _ : A P\nancer arn Expression Level ee, DI.1 expression (Positive)\noO\n+ > 25% of tumor cells exhibit membrane staining; or,\n: F ICP > 1% and IC~ > 25%: or, High PDI.1 expression\nthelial °\nro ma 1 - ICP = 1% and IC+ = 100%\n\\Carcinoma ; — -\nNone of the criteria for PID-I.1 High Status are met. ow: Negative PD-LI\nXpTession\nservical Carcinoma’ Ft No PDL expression\n(Cervical Carcinoma P\nH - 1 IPDI.1 expression\neadandNeck [2S SSN PTT pression —_]\na ce cc\noe 4 10 IPIDI.1 expression\n\\Carcinoma’\nmpleNegawve fs SSN Pepsin |\nBreast Carcinoma . :\n{Other tumor types!\nReferences:\n1. Ventana PID-I.1 SP263 Interpretation Manual for NSCLC and Urothelial Carcinoma.\n2. Marletta S, Fusco N, Munani FE et al. Atlas of PD-L.1 for Pathologists: Indications, Scores, Diagnostic\nPlatforms and Reporting Systems. J Pers Med 2022 Jun 29;12(7):1073. doi: 10.3390/pm 12071073.\n3. Pai T, Aiyer HM, Kulkami B, Vidya MN, Patne S, Sewlikar S, et al. Role of PD-I.1 SP263 Assay in Cancer\nImmunotherapy: A Comprehensive Review. J Cancer Immunol. 2024;6(2):77-91.\n4. Extrapolated from 22c3 interpretation guidelines To be interpreted with caution with clinical correlation.",
                "impression": "No PDL! expression seen.",
                "macroscopicFindings": "Received by Mr. Anjan\nReceived three unstained coated slides labelled as 56568\nSlides identified based on the label and previous copy",
                "microscopicDescription": "Immunohistochemistry:\nImmunohistochemistry done on slide - 56568\nPercentage of tumor cells with membrane staining for PD-L.1: <1%\nNumber of PID-I.1 staining cells (Tumor cells ~ Immune cells): 1\nTotal number of viable tumor cells: 275\nCombined proportion score (CPS): 0.36",
                "note": "PDI.1 IHC (clone Ventana SP 263) is an FDA approved companion diagnostic for selecting patients for\nimmunotherapy.\nThis assay is performed on Ventana BenchMark Ultra.\nTumour cells and mononuclear inflammatory cells (within tumour nests or adjacent supporting stroma) with partial\nor complete linear membrane staining of at least 1+ intensity are scored as positive. The combined positive score is\nestimated by manual quantification.\nThe test is performed if > 100 tumour cells are present.\nCertain tissue processing factors, such as decalcification, formalin fixation time outside an acceptable range (< 3\nhours), prolonged time to fixation and use of tissue from blocks that are 6 months or older, can affect PII. staining /\nexpression and results should be interpreted with caution in such instances.\nThis assay is not validated for decalcified specimens.\nAll controls show appropniate reactivity.\n* This report is not valid for partial / divided specimens.Slides and blocks will be issued after 2 days of written request.\nReporting is done on Digital pathology images (WSI) & / or Microscopy.",
                "specimen": "Slides for immunohistochemistry - PDI.1 by SP263"
            }
        ],
        "test": "IHC Report"
    },
    "extracted_text": "Deel\n—e rs ‘. “\na ; Dae a H G\nSciences Aba Ves\nPrec son C.agnost cs lol gap adding Life to years\nPatient Name : Mr. SURESH KACHARU SHIROSE Collected : 16/May/2025 04:08PM\nAge/Gender : 45 Years/M Received 1 17/May/2025 10:28AM\nUHID/MR No : ABSC.0000004103 Reported 1 21/May/2025 11:53AM\nVisit ID : ABSC4104 Status : Final Report\nRef Doctor : Or.Or. Sreekanth Reddy Client Name : 4BASECARE PRECISION HEALTH PVT LTD\nCase Id : H-11723/25 Ward Name :\nIMMUNOHISTOCHEMISTRY REPORT\nPDL1- [HC\nClinical Case of carcinoma thyroid in bone\nHistory:\nSpecimen: | Slides for immunohistochemistry - PDI.1 by SP263\nMacroscopic | Received by Mr. Anjan\nfindings: Received three unstained coated slides labelled as 56568\nSlides identified based on the label and previous copy\nMicroscopic | Immunohistochemistry:\ndescription: | Immunohistochemistry done on slide - 56568\nPercentage of tumor cells with membrane staining for PD-L.1: <1%\nNumber of PID-I.1 staining cells (Tumor cells ~ Immune cells): 1\nTotal number of viable tumor cells: 275\nCombined proportion score (CPS): 0.36\nImpression: |No PDL! expression seen.\nComments: |PDI.1 interpretation:\nClone: Roche SP263\nSite umor Cell score (TC) omb ined Proportion Score Result\nCPS)\nPD-L.1 Expression Level No PIDL.1 expression\n[Non-Small Cell Lung}< 1% Negative)\nIk 1,2 _ : A P\nancer arn Expression Level ee, DI.1 expression (Positive)\noO\n+ > 25% of tumor cells exhibit membrane staining; or,\n: F ICP > 1% and IC~ > 25%: or, High PDI.1 expression\nthelial °\nro ma 1 - ICP = 1% and IC+ = 100%\n\\Carcinoma ; — -\nNone of the criteria for PID-I.1 High Status are met. ow: Negative PD-LI\nXpTession\nservical Carcinoma’ Ft No PDL expression\n(Cervical Carcinoma P\nH - 1 IPDI.1 expression\n21-May-2025 12:25 PM Page 1 of 3\n1 i hoe ey 1 I : . 1 ‘ ' m4\n\n\n5 Slee AE\nSciences Aba Ves\nPrec sen C.agagst cs fol LD adding life to years.\nPatient Name : Mr. SURESH KACHARU SHIROSE Collected : 16/May/2025 04:08PM\nAge/Gender : 45 Years/M Received 1 17/May/2025 10:28AM\nUHID/MR No : ABSC.0000004103 Reported : 21/May/2025 11:53AM\nVisit ID : ABSC4104 Status : Final Report\nRef Doctor : Or.Or. Sreekanth Reddy Client Name : 4BASECARE PRECISION HEALTH PVT LTD\nCase Id : H-11723/25 Ward Name :\nIMMUNOHISTOCHEMISTRY REPORT\nPDL1- [HC\neadandNeck [2S SSN PTT pression —_]\na ce cc\nCt\noe 4 10 IPIDI.1 expression\n\\Carcinoma’\nmpleNegawve fs SSN Pepsin |\nBreast Carcinoma . :\n{Other tumor types!\nNote:\no PDI.1 IHC (clone Ventana SP 263) is an FDA approved companion diagnostic for selecting patients for\nimmunotherapy.\n0 This assay is performed on Ventana BenchMark Ultra.\no Tumour cells and mononuclear inflammatory cells (within tumour nests or adjacent supporting stroma) with partial\nor complete linear membrane staining of at least 1+ intensity are scored as positive. The combined positive score is\nestimated by manual quantification.\no The test is performed if > 100 tumour cells are present.\no Certain tissue processing factors, such as decalcification, formalin fixation time outside an acceptable range (< 3\nhours), prolonged time to fixation and use of tissue from blocks that are 6 months or older, can affect PII. staining /\nexpression and results should be interpreted with caution in such instances.\n0 This assay is not validated for decalcified specimens.\no All controls show appropniate reactivity.\nReference:\n1. Ventana PID-I.1 SP263 Interpretation Manual for NSCLC and Urothelial Carcinoma.\n2. Marletta S, Fusco N, Munani FE et al. Atlas of PD-L.1 for Pathologists: Indications, Scores, Diagnostic\nPlatforms and Reporting Systems. J Pers Med 2022 Jun 29;12(7):1073. doi: 10.3390/pm 12071073.\n3. Pai T, Aiyer HM, Kulkami B, Vidya MN, Patne S, Sewlikar S, et al. Role of PD-I.1 SP263 Assay in Cancer\nImmunotherapy: A Comprehensive Review. J Cancer Immunol. 2024;6(2):77-91.\n4. Extrapolated from 22c3 interpretation guidelines To be interpreted with caution with clinical correlation.\nSlides enclosed\nNote:\n* This report is not valid for partial / divided specimens.Slides and blocks will be issued after 2 days of written request.\nReporting is done on Digital pathology images (WSI) & / or Microscopy.\n21-May-2025 12:25 PM Page 2 of 3\ni Poa: cr rr Were whet, 2 ee en m4\n\n\nBespegce\n—e ~© ‘. fa\n_ ; $35 fh H G\nSciences Aba Ves\n\nPrec sion C.agnos? cs lee AS adding life to years\n\nPatient Name : Mr. SURESH KACHARU SHIROSE Collected : 16/May/2025 04:08PM\n\nAge/Gender : 45 Years/M Received 1 17/May/2025 10:28AM\n\nUHID/MR No : ABSC.0000004103 Reported : 21/May/2025 11:53AM\n\nVisit ID : ABSC4104 Status : Final Report\n\nRef Doctor : Or.Or. Sreekanth Reddy Client Name : 4BASECARE PRECISION HEALTH PVT LTD\n\nCase Id : H-11723/25 Ward Name :\n\nIMMUNOHISTOCHEMISTRY REPORT\nPDL1- [HC\nDigital slide images are available on request.\nEntered By : Verified By: Approved By :\nLA. :\nriya . sgaonkar Dr Veena R., MD(Pathology)\nDNB Resident KMC No.: 44080\nSunitha Chikerre KMC No.: 5104 Sr Consultant Pathologist\n*** End Of Report. ***\nSIN No TH6005339 ACCR EDITED\nCOLLEGE of AMERICAN PATHOLOGISTS\n21-May-2025 12:25 PM Page 3 of 3\n' ' \" ‘, I i .\n\n\n",
    "extraction_method": "gemini_2.0_flash",
    "file_path": "C:\\Users\\chinmay alse\\Desktop\\batch\\IN-423-YENAP_Ventana Negative.pdf",
    "file_processed": "IN-423-YENAP_Ventana Negative.pdf",
    "keywords_identified": [
        "4basecare",
        "hcg",
        "immunohistochemistry"
    ],
    "processing_time": "57.34 seconds",
    "reason": "",
    "report_type": "IHC_HCG",
    "success": true,
    "timestamp": "2025-06-01 15:48:25",
    "verified_text": "{\n  \"test\": \"IHC Report\",\n  \"hospital_lab_name\": \"Triesta Sciences\",\n  \"hospital_lab_location\": \"HCG Towers, # 8, P Kalinga Rao Road, Sampangiram Nagar, Bangalore - 560 027\",\n  \"Patient Name\": \"Mr. SURESH KACHARU SHIROSE\",\n  \"parameters\": [\n    {\n      \"clinicalHistory\": \"Case of carcinoma thyroid in bone\",\n      \"specimen\": \"Slides for immunohistochemistry - PDL1 by SP263\",\n      \"macroscopicFindings\": \"Received by Mr. Anjan Received three unstained coated slides labelled as 56568 Slides identified based on the label and previous copy\",\n      \"microscopicDescription\": \"Immunohistochemistry done on slide - 56568 Percentage of tumor cells with membrane staining for PD-L1: <1% Number of PD-L1 staining cells (Tumor cells + Immune cells): 1 Total number of viable tumor cells: 275 Combined proportion score (CPS): 0.36\",\n      \"impression\": \"No PDL1 expression seen.\",\n      \"comments\": \"PDL1 interpretation: Clone: Roche SP263 Site Non-Small Cell Lung Cancer Urothelial Carcinoma Cervical Carcinoma Head and Neck Carcinoma Esophageal Squamous Cell Carcinoma Triple Negative Breast Carcinoma (TNBC) Other tumor types References: 1. Ventana PD-L1 SP263 Interpretation Manual for NSCLC and Urothelial Carcinoma. 2. Marletta S, Fusco N, Munani FE et al. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. J Pers Med 2022 Jun 29;12(7):1073. doi: 10.3390 pm12071073. 3. Pai T, Aiyer HM, Kulkarni B, Vidya MN, Patne S, Sewlikar S, et al. Role of PD-L1 SP263 Assay in Cancer Immunotherapy: A Comprehensive Review. J Cancer Immunol. 2024;6(2):77-91. 4. Extrapolated from 22c3 interpretation guidelines \\u2013 To be interpreted with caution with clinical correlation.\",\n      \"note\": \"PDL1 IHC (clone Ventana SP 263) is an FDA approved companion diagnostic for selecting patients for immunotherapy. This assay is performed on Ventana BenchMark Ultra. Tumour cells and mononuclear inflammatory cells (within tumour nests or adjacent supporting stroma) with partial or complete linear membrane staining of at least 1+ intensity are scored as positive. The combined positive score is estimated by manual quantification. The test is performed if > 100 tumour cells are present. Certain tissue processing factors, such as decalcification, formalin fixation time outside an acceptable range (< 3 hours), prolonged time to fixation and use of tissue from blocks that are 6 months or older, can affect PDL1 staining expression and results should be interpreted with caution in such instances. This assay is not validated for decalcified specimens. All controls show appropriate reactivity. * This report is not valid for partial divided specimens.Slides and blocks will be issued after 2 days of written request. Reporting is done on Digital pathology images (WSI) & or Microscopy.\"\n    }\n  ]\n}"
}